Researchers Develop Blood Test That May Detect Testicular Cancer Missed by Standard Markers
Mayo Clinic researchers have developed a blood test that detected 93% of germ cell tumors—including cases missed by standard markers.
Latest Articles
Editor's Top Picks
FDA Grants Breakthrough Status to Blood Test to Distinguish Schizophrenia and Bipolar Disorder
The mRNA-based test aims to provide objective data to help clinicians distinguish between psychiatric conditions that often share symptoms.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
ClearNote Health to Present Pancreatic Cancer Test Data at DDW 2026
ClearNote Health will present data at DDW 2026 showing its Avantect Pancreatic Cancer Test achieved 82.6% sensitivity and 97.5% specificity in patients at elevated risk.
Equipment & Supply Spotlight
New Automated Blood Culture System Receives CE Mark for Infection Diagnosis
The BD BACTEC FXI Culture System has received CE marking under EU IVDR, offering automated blood culture diagnostics with a reported 15% faster pathogen detection than previous models, according to clinical study data.
News, Know-How & Standards
Disease Detection & Understanding
Creatv Bio’s Liquid Biopsy Test Supports CytoDyn Phase 2 Colorectal Cancer Study
LifeTracDx blood test will evaluate PD-L1 expression changes as exploratory biomarker in trial combining leronlimab with standard therapies.
